Investigation of the Safety and Effectiveness of a Trifocal IOL

NCT04176965 | Completed Results FDA Device

• 1 other identifier: PHY1903
• Study Type: interventional
• Target: 539
• Locations: 1 country
• Sites: 20

Brief Summary

This study is a prospective, multicenter, randomized, double masked confirmatory trial comparing an investigational trifocal intraocular lens (IOL) and a commercially available monofocal IOL.

Conditions

Eye Diseases; Postcataract Aphakia; Cataract; Lens Opacities

Keywords

Intraocular Lens; Multifocal; Hydrophobic

Outcome Measures

Primary Outcomes (7)

• Mean Photopic Monocular logMAR Best Corrected Distance Visual Acuity (BCDVA) at 4 Meters in First Operative Eyes

  Visual acuity (VA) was tested monocularly (each eye separately) under photopic (well-lit) conditions using the correction obtained from the manifest refraction and electronic Early Treatment Diabetic Retinopathy Study (ETDRS) charts on a CTS (Clinical Trial Suite, M\&S Technologies) device at a distance of 4 meters (m) from the eye. VA was measured in logarithm of the minimum angle of resolution (logMAR), with 0.02 logMAR increment corresponding to a single letter on an ETDRS chart. A lower or negative value represents better visual acuity. The mean logMAR values of the two groups were compared to demonstrate non-inferiority of FINEVISION HP trifocal IOL to the control IOL in mean photopic monocular logMAR BCDVA (best corrected distance visual acuity) for the first operative eyes.

  150-180 days after surgery on the first eyes

• Mean Photopic Monocular logMAR Distance Corrected Near Visual Acuity (DCNVA) for the First Operative Eyes.

  VA was tested monocularly under photopic (well-lit) conditions using the manifest refraction adjusted for optical infinity and electronic ETDRS charts at a distance of 40 centimeters (cm) from the eye. Distance corrected visual acuity at near was measured in logMAR, with 0.02 logMAR increment corresponding to a single letter on an ETDRS chart. A lower value represents better visual acuity. The mean logMAR values of the two groups were compared to demonstrate superiority of FINEVISION HP trifocal IOL to the control in mean photopic monocular logMAR DCNVA for the first operative eyes.

  150-180 days after surgery on the first eyes

• Percentage of 1st Operative Eyes With Secondary Surgical Interventions (SSIs) Related to Optical Properties of IOL for up to Month 12 (Visit 5)

  The number of SSI's related to the optical properties of the IOL was calculated from the time of implantation up to Month 12. The percentage of SSIs was calculated as (# of first operative eyes with an SSI related to the optical properties of the IOL) divided by (# of first operative eyes with successful IOL implantation) times 100. The percentages were compared in the two groups to demonstrate noninferiority of FINEVISION HP IOL compared to AcrySof SN60AT IOL.

  Up to Month 12 (Day 360-420), post first eye implantation

• Mean Monocular Distance Log Contrast Sensitivity Photopic Without Glare at 2.5 m in 1st Operative Eyes at Month 12 (Visit 5).

  Contrast sensitivity (the ability to detect objects by distinguishing them from their background) was measured monocularly under photopic (well-lit) conditions without glare source in log units using the Clinical Trial Suite (M\&S Technologies) for sine-wave gratings 3, 6, 12, and 18 cycles per degree (CPD) at a test distance of 2.5 meters with best-corrected manifest refraction at 4 meters in place with an adjustment of +0.12 D for the 2.5-meter test distance. A more negative numeric log value represents better contrast sensitivity. Hypothesis testing was not planned for this outcome measure.

  Month 12 (Day 360-420), post-first eye implantation

• Mean Monocular Distance Log Contrast Sensitivity Photopic With Glare at 2.5 m in 1st Operative Eyes at Month 12 (Visit 5).

  Contrast sensitivity (the ability to detect objects by distinguishing them from their background) was measured monocularly under photopic (well-lit) conditions with a glare source in log units using the Clinical Trial Suite (M\&S Technologies) for sine-wave gratings 3, 6, 12, and 18 cycles per degree (CPD) at a test distance of 2.5 meters with best-corrected manifest refraction at 4 meters in place with an adjustment of +0.12 D for the 2.5-meter test distance. A more negative numeric log value represents better contrast sensitivity. Hypothesis testing was not planned for this outcome measure.

  Month 12 (Day 360-420), post-first eye implantation

• Mean Monocular Distance Log Contrast Sensitivity Mesopic Without Glare at 2.5 m in 1st Operative Eyes at Month 12 (Visit 5).

  Contrast sensitivity (the ability to detect objects by distinguishing them from their background) was measured monocularly under mesopic (dim-lit) conditions without glare source in log units using the Clinical Trial Suite (M\&S Technologies) for sine-wave gratings 1.5, 3, 6, and 12 cycles per degree (CPD) at a test distance of 2.5 meters with best-corrected manifest refraction at 4 meters in place with an adjustment of +0.12 D for the 2.5-meter test distance. A more negative numeric log value represents better contrast sensitivity. Hypothesis testing was not planned for this outcome measure.

  Month 12 (Day 360-420), post-first eye implantation

• Mean Monocular Distance Log Contrast Sensitivity Mesopic With Glare at 2.5 m in 1st Operative Eyes at Month 12 (Visit 5).

  Contrast sensitivity (the ability to detect objects by distinguishing them from their background) was measured monocularly under mesopic (dim-lit) conditions with a glare source in log units using the Clinical Trial Suite (M\&S Technologies) for sine-wave gratings 1.5, 3, 6, and12 cycles per degree (CPD) at a test distance of 2.5 meters with best-corrected manifest refraction at 4 meters in place with an adjustment of +0.12 D for the 2.5-meter test distance. A more negative numeric log value represents better contrast sensitivity. Hypothesis testing was not planned for this outcome measure.

  Month 12 (Day 360-420), post-first eye implantation

Secondary Outcomes (3)

• Mean Photopic Monocular logMAR Distance Corrected Intermediate Visual Acuity (DCIVA) at 66 cm for the First Operative Eyes.

  150-180 days after surgery on the first eye

• Number and Percentage of First Operative Eyes With Cumulative and Persistent Adverse Events at Month 12 (Visit 5) in Comparison to the ISO Safety and Performance Endpoint (SPE) Rates as Described in ISO 11979-7

  Month 12 (Day 360-420), post-first eye implantation

• Evaluate Visual Disturbances Using the Quality of Vision (QoV) Questionnaire and QoV Supplemental Questions at Month 12 (Visit 5)

  Month 12 (Day 360-420), post-first eye implantation

Study Arms (2)

FINEVISION HP

EXPERIMENTAL

Trifocal FINEVISION HP. Cataractous lens will be removed in the study eyes and the FINEVISION HP will be implanted in the capsular bag.

Device: FINEVISION HP IOL

Control Product

ACTIVE COMPARATOR

Cataractous lens will be removed in the study eyes and the Alcon AcrySof® SN60AT IOL will be implanted in the capsular bag.

Device: Alcon AcrySof SN60AT

Interventions

FINEVISION HP IOL DEVICE

Cataractous lens will be removed in the study eyes and the FINEVISION HP IOL will be implanted in the capsular bag.

FINEVISION HP

Alcon AcrySof SN60AT DEVICE

Cataractous lens will be removed in the study eyes and the Alcon AcrySof SN60AT IOL will be implanted in the capsular bag.

Control Product

Eligibility Criteria

• Age: 22 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female adults, age 22 years or older at the Preoperative Visit.
• Visually significant cataracts in both eyes that are eligible for phacoemulsification cataract surgery.
• Willing to undergo cataract surgery in the second operative eye within 7 - 30 days after surgery in the first eye.
• Projected Best Corrected Distance Visual Acuity (BCDVA) of 0.2 logMAR (20/32 Snellen) or better in each eye after cataract surgery/IOL implantation, as determined by the medical judgement of the Investigator
• Eligible for receipt of an IOL power within the range of the investigational IOL (+10.0 D to +30.0 D, in 0.50 D increments) in each eye
• Contact lens users must be willing to discontinue wear of their lenses in accordance with the following requirements:
• Rigid gas permeable lenses for ≥ 7 days prior to the Preoperative Visit
• Soft contact lenses for ≥ 3 days prior to the Preoperative Visit Contact lens wearers must demonstrate a stable refraction (within ±0.50 D for both sphere and cylinder) in each eye, as determined by manifest refraction on two consecutive examination dates at least one week apart after discontinuation of contact lens wear.
• Provide signed written consent prior to participation in any study-related procedures.
• Ability, comprehension, and willingness to follow study instructions, and likely to complete all study visits.
• Female subjects must be 1-year postmenopausal, surgically sterilized, or, if of childbearing potential, have a negative urine pregnancy test at the Preoperative Visit. Women of childbearing potential must use an acceptable form of contraception throughout the study. Acceptable methods include at least one of the following: intrauterine (intrauterine device), hormonal (oral, injection, patch, implant, ring), barrier with spermicide (condom, diaphragm), or abstinence.

You may not qualify if:

• History or presence of, or predisposition to, degenerative visual disorders (e.g., macular degeneration, retinal detachment, proliferative diabetic retinopathy, or other retinal disorders) predicted to result in BCDVA worse than 0.2 LogMAR (20/32 Snellen) in either eye during the study participation period.
• Significant anterior segment pathology in either eye that might increase intraoperative risk or compromise IOL stability (e.g., pseudoexfoliation syndrome)
• Reasonably expected to require secondary ocular surgical intervention or laser treatment other than YAG capsulotomy in either eye during the study participation period.
• Presence of one or more clinically significant corneal abnormalities in either eye, including corneal dystrophy, irregularity, or edema per the Investigator's medical opinion.
• Previous intraocular, corneal, or retinal detachment surgery, including corneal transplant, LASIK, astigmatic keratotomy and limbal relaxing incisions in either eye
• Rubella, congenital, traumatic or complicated cataract in either eye
• Preoperative keratometric astigmatism \> 1.0 D or irregular corneal astigmatism in either eye (Note: corneal incisions intended to reduce astigmatism are not permitted)
• Clinically significant ocular inflammation or infection present ≤ 30 days in either eye prior to the Preoperative Visit.
• Presence or history of one or more severe/serious ocular conditions (e.g., glaucoma, uveitis, ocular infection, severe dry eye) in either eye, or any other unstable medical condition (e.g., uncontrolled diabetes) that in the opinion of the Investigator would put the subject's health at risk, confound the results of the study and/or prevent the subject from completing all study visits.
• Use of medications known to interfere with visual performance, pupil dilation, or iris structure ≤ 30 days prior to the Preoperative Visit.
• Participation in any study of an investigational, interventional product within 30 days prior to the Preoperative Visit or at any time during the study period.
• Pregnant or nursing females.

Sponsors & Collaborators

• Beaver-Visitec International, Inc.: lead

Study Sites (20)

Mitchell C Shultz MD/Shultz Chang Vision

Northridge, California, 91325, United States

Location

Coastal Vision Medical Group

Orange, California, 92868, United States

Location

Arbor Centers for Eye Care

Orland Park, Illinois, 60467, United States

Location

Michael Washburn Center for Ophthalmic Research

Indianapolis, Indiana, 46240, United States

Location

Vance Thompson Vision, MN Site

Alexandria, Minnesota, 56308, United States

Location

Chu Vision Institute

Bloomington, Minnesota, 55420, United States

Location

Ophthalmology Consultants, Ltd

St Louis, Missouri, 63131, United States

Location

Vance Thompson Vision, MT Site

Bozeman, Montana, 59718, United States

Location

Vance Thompson Vision NE Site

Omaha, Nebraska, 68137, United States

Location

Center For Sight

Las Vegas, Nevada, 89145, United States

Location

Eye Associates & SurgiCenter

Vineland, New Jersey, 08361, United States

Location

Vance Thompson Vision ND Site

West Fargo, North Dakota, 58078, United States

Location

Cleveland Eye Clinic

Brecksville, Ohio, 44141, United States

Location

Associates in Ophthalmology Ltd

West Mifflin, Pennsylvania, 15122, United States

Location

Vance Thompson Vision. SD Site

Sioux Falls, South Dakota, 57108, United States

Location

Key-Whitman Eye Center

Dallas, Texas, 75243, United States

Location

Lehmann Eye Center

Nacogdoches, Texas, 75965, United States

Location

Parkhurst Nuvision

San Antonio, Texas, 78229, United States

Location

The Eye Institute of Utah

Salt Lake City, Utah, 84107, United States

Location

Piedmont Eye Center

Lynchburg, Virginia, 24502, United States

Location

MeSH Terms

Conditions

Eye Diseases; Aphakia, Postcataract; Cataract

Condition Hierarchy (Ancestors)

Aphakia; Lens Diseases

Results Point of Contact

• Title: Rebecca McQuaid
• Organization: BVI medical

RMcQuaid@bvimedical.com

+353871212615

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Masking Details: In order to minimize bias, site personnel performing postoperative study assessments of visual performance will be masked to subject treatment assignment until after the final database lock ("masked assessors").
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Approximately 501 subjects will be screened across up to 24 study sites to complete 300 subjects implanted bilaterally with the FINEVISION HP and 150 subjects implanted bilaterally with the control monofocal Alcon AcrySof SN60AT.

Study Record Dates

• First Submitted: November 20, 2019
• First Posted: November 26, 2019
• Study Start: April 28, 2022
• Primary Completion: May 13, 2024
• Study Completion: May 13, 2024
• Last Updated: January 29, 2025
• Results First Posted: January 29, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (20)